Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Google Secures Pentagon AI Deal for Classified Projects 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
VANCOUVER, British Columbia, April 25, 2017 -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main, Aquinox President & CEO, will present a corporate overview at the upcoming 2017 Annual Bloom Burton & Co. Healthcare Investor Conference in Toronto on Tuesday, May 2nd 2017 at 9:30 AM Eastern Time.
A live audio webcast and archive of the event will be available at: http://www.wsw.com/webcast/bloomburton/aqxp/
To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Relations page of the Aquinox website. The corporate overview being presented will be available following the presentation at www.aqxpharma.com.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a late clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Our primary focus is anti-inflammatory product candidates targeting SH2-containing inositol-5'-phosphatase 1, or SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. In September 2016, we began enrolling patients in a Phase 3 clinical trial of AQX-1125 in our lead indication, Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). Other indications are under consideration for future investigation. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1. For more information, please visit www.aqxpharma.com.
Investor Contact Info:
Brendan Payne
Senior Manager, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.629.9223 Ext. 109
[email protected]
Gitanjali Ogawa
Vice President
The Trout Group
646-378-2949
[email protected]
